Across TCGA pan-cancer cohorts, PABPC1P2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PABPC1P2 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PABPC1P2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PABPC1P2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, UCEC, and COAD are the cancer types where PABPC1P2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	IV	0.135	0.650	.001	12	view →
UCEC	DFS	Median	II,III,IV	0.922	0.438	.032	8	view →
COAD	DFS	Median	IV	0.028	0.496	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: PABPC1P2 tumor-vs-normal RNA expression · all PABPC1P2 data types